Pinned Tweet
@JNCI_Now We defined the gene expression profiles distinguishing HPV+ OPSCCs that are prone to recur after TORS-based therapy. These the tumor-intrinsic and immune-related traits were tightly interrelated and generalizeable to nonsurgical cases as well. academic.oup.com/jnci/advance-a…
3
4
26
2,588
Devraj Basu, MD, PhD, FACS retweeted
Publishing in our current system involves an enormous amount of wasted mental cycles by some of the smartest people on the planet. Hmm.
4
7
95
5,808
Well written review by @imrtlee @xrtGenomics et al and an easy read for the non-rad onc, contextualizing differences between the two phase III trials comparing IMRT to IMPT for oropharyngeal cancer. ascopubs.org/doi/full/10.12…
0
1
4
222
Devraj Basu, MD, PhD, FACS retweeted
🦠💡Next up - TRINITY trial presented by Zachary Zumsteg at @CedarsSinai, investigating reduced dose/volume CRT after TORS with excellent 2-yr PFS.
#ASTRO26 @ASTRO_org
@xrtGenomics @DanielMaMD @RobertFerrisMD @drdavidpalma
#ASTRO26 @ASTRO_org
@xrtGenomics @DanielMaMD @RobertFerrisMD @drdavidpalma
1
7
12
905
Devraj Basu, MD, PhD, FACS retweeted
So proud to be a Pennsylvanian with a Republican Senator like Dave McCormick. Thank you Senator McCormick for strongly supporting biomedical research and NIH.
washingtonpost.com/opinions/2026/…
washingtonpost.com/opinions/2026/…
1
1
35
3,469
Highlighting our infographic with @AHNS on the significance of discordant HPV confirmatory testing in p16+ oropharyngeal cancer and current US guidelines for using it.
Presented by the AHNS Annual Basic & Translational Science Service. Prepared by @MollyEHeftNeal and @BasuLab1, this infographic explores HPV/p16 discordance in oropharyngeal cancer, its prognostic & therapeutic relevance, and implications for confirmatory HPV testing.
#AHNS
3
1
4
691
Devraj Basu, MD, PhD, FACS retweeted
Very thoughtful commentary from the stellar Red Journal H&N editors!
redjournal.org/article/S0360-…
redjournal.org/article/S0360-…
3
3
14
3,915
Devraj Basu, MD, PhD, FACS retweeted
Question born in a clinic. 74 patients with HNSCC undergoing CTRT. Two blinded oncologists grading toxicities.
Now in Red Journal
Mucositis, ≥G2 κ: 0.23–0.41 | 91.9% vs 70.2%,
Assessor = hidden covariate in every tox endpoint
doi.org/rmn6
@IJROBP @RadOncTMC
Now in Red Journal
Mucositis, ≥G2 κ: 0.23–0.41 | 91.9% vs 70.2%,
Assessor = hidden covariate in every tox endpoint
doi.org/rmn6
@IJROBP @RadOncTMC
2
13
37
3,027
Devraj Basu, MD, PhD, FACS retweeted
The final paper from Gough/Crittenden Lab @providence is out in J of Immunology.
Kaede tracking shows the tumor-draining lymph node refills irradiated tumors with T cells — support for lymphatic-sparing immunoradiotherapy in H&N cancer. academic.oup.com/jimmunol/artic…
Kaede tracking shows the tumor-draining lymph node refills irradiated tumors with T cells — support for lymphatic-sparing immunoradiotherapy in H&N cancer. academic.oup.com/jimmunol/artic…
0
2
5
279
Devraj Basu, MD, PhD, FACS retweeted
Updated results from JCOG 1008 (bolus versus weekly cis for postoperative CRT in high-risk patients) are out.
Weekly cisplatin was clearly non-inferior and in fact numerically superior from both a disease- and safety- perspective. The clear winner.
It will be very interesting to see the final results from HN009 (definitive CRT), especially in an HPV-negative population that may be at higher risk for treatment-related toxicity.
ascopubs.org/doi/full/10.12…
Weekly cisplatin was clearly non-inferior and in fact numerically superior from both a disease- and safety- perspective. The clear winner.
It will be very interesting to see the final results from HN009 (definitive CRT), especially in an HPV-negative population that may be at higher risk for treatment-related toxicity.
ascopubs.org/doi/full/10.12…
1
14
34
2,392
Dr Gillison played a central role in elucidating the clinical and molecular epidemiology of HPV+ oropharyngeal cancer and made critical contributions to our understanding of HPV genome states in malignancy.
Rest in peace Maura.
Oncology has lost a brilliant and compassionate physician scientist.
0
0
9
1,145
Devraj Basu, MD, PhD, FACS retweeted
Mark was a phenomenal human being and leader - a great loss.
Mark A. Varvares, MD, FACS, passed away on May 20, 2026 surrounded by his family leaving behind a legacy defined by the countless lives he has touched
Viewing and funeral service will be Saturday, May 30th, St Nicholas Greek Orthodox Church in St Louis, MO
buff.ly/iORf2w8
1
1
3
1,205
Some interesting results to unpack here
Sharing the results of ReACT 1.0 in @NatureComms -- the first study to use HPV ctDNA to guide CRT de-escalation in higher risk HPV+ OPC. ctDNA metrics may improve risk stratification. Grateful to our coauthors. @Naveris_inc @DanaFarberNews @jdschoenfeld1
nature.com/articles/s4146…
0
0
1
226